PUBBLICAZIONI SCIENTIFICHE
Consultabili nei Cv dei singoli Dirigenti Medici
Two dosage interferon-alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial.
Offidani M, Olivieri A, Montillo M, Rupoli S, Centurioni R, Alesiani F, Marchegiani G, Pieroni S, Catarini M, Pelliccia G, Altilia F, Leoni P.
Haematologica. 1998; 83(1):40-7.
Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
Offidani M, Marconi M, Corvatta L, Olivieri A, Catarini M, Leoni P.
Haematologica. 2003; 88(12):1432-3.
Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort study.
Offidani M, Corvatta L, Malerba L, Marconi M, Bichisecchi E, Cecchini S, Manso E, Principi T, Gasparini S, Leoni P.
Cancer. 2004; 101(3):567-77.
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Piersantelli MN, Leoni P.
Haematologica. 2006; 91(1):133-6.
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.
Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P.
Blood. 2006;108(7):2159-64.
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Offidani M, Corvatta L, Polloni C, Piersantelli MN, Gentili S, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Samori A, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P.
Br J Haematol. 2009; 144(5):653-9.
Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M, Giuliodori L, Leoni P.
Clin Lymphoma Myeloma Leuk. 2012; 12(6):423-32.
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.
Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P, Olivieri A, Leoni P.
Blood Cancer J. 2013; 22;3:
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma.
Offidani M, Boccadoro M, Di Raimondo F, Petrucci MT, Tosi P, Cavo M.
Curr Hematol Malig Rep. 2019; 14(3):187-196.
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M, Corvatta L, Morè S, Nappi D, Martinelli G, Olivieri A, Cerchione C.
Front Oncol. 2021 Feb 17;10:624-661.
Novel Experimental Drugs for Treatment of Multiple Myeloma.
Offidani M, Corvatta L, Morè S, Olivieri A.
J Exp Pharmacol. 2021 Mar 9;13:245-264.
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M, Corvatta L, Morè S, Olivieri A
Drug Des Devel Ther. 2021 Jun 2;15:2401-2415.
Gini G, Cimminiello M, Galieni P, Hohaus S, Nassi L, Picardi M, Romano A, Tarantini G.
Advanced Stage Hodgkin Lymphoma: Patient Management.
Acta Biomed. 2020 May 25;91(S-5):5-12. doi: 10.23750/abm.v91iS-5.9913.PMID: 32525129
Olivieri A, Saraceni F. Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean. Bone Marrow Transplant. 2016 Mar;51(3):348-50. doi: 10.1038/bmt.2015.317. Epub 2015 Dec 21. PMID: 26691418.
Olivieri A. et al, Blood 2009 Imatinib for refractory chronic graft-versus-host disease with fibrotic features doi: 10.1182/blood-2009-02-204156.
Olivieri A. et al, Blood 2013 Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. doi: 10.1182/blood-2013-05-494278.
Svegliati S*, Olivieri A*, (* equally contributed) et al, Blood 2007 Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. doi: 10.1182/blood-2007-01-071043.
Olivieri A, Mancini G, Olivieri J, Marinelli Busilacchi E, Cimminiello M, Pascale SP, Nuccorini R, Patriarca F, Corradini P, Bacigalupo A, Angelini S, Poloni A, Grillo G, Onida F, Martino M, Di Renzo N, Nagler A, Mordini N, Bruno B, Ciceri F, Bonifazi F. Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). Bone Marrow Transplant. 2020 Nov;55(11):2077-2086. doi: 10.1038/s41409-020-0902-9. Epub 2020 Apr 24. PMID: 32332918.
LIBRI: